TerminatedNot Applicable

Biomarker for Alport Syndrome (BioAlport)

Stopped: Study no longer pursued.

Albania, Georgia, India12 participantsStarted 2018-08-20

Plain-language summary

International, multicenter, observational, longitudinal monitoring study to identify biomarker/s for Alport syndrome and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s

Who can participate

Age range2 Months – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

INCLUSION CRITERIA * Informed consent is obtained from the participant or the parent/ legal guardian. * The participant is aged between 2 months and 50 years * The diagnosis of Alport Syndrome is genetically confirmed by CENTOGENE EXCLUSION CRITERIA * Informed consent is not obtained from the participant or from the parent/ legal guardian * The participant is younger than 2 months or older than 50 years * The diagnosis of Alport Syndrome is not genetically confirmed by CENTOGENE

What they're measuring

Identification of Alport Syndrome biomarker/s

Timeframe: 36 months

Trial details

NCT IDNCT02718027

SponsorCENTOGENE GmbH Rostock

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-12-31

View on ClinicalTrials.gov More Nephritis, Hereditary trials